Detalles de la búsqueda
1.
Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations.
Br J Haematol
; 194(4): 708-717, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34296432
2.
A new prognostic model identifies patients aged 80 years and older with diffuse large B-cell lymphoma who may benefit from curative treatment: A multicenter, retrospective analysis by the Spanish GELTAMO group.
Am J Hematol
; 93(7): 867-873, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29658143
3.
Dinaciclib synergizes with BH3 mimetics targeting BCL-2 and BCL-XL in multiple myeloma cell lines partially dependent on MCL-1 and in plasma cells from patients.
Mol Oncol
; 17(12): 2507-2525, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37704591
4.
Ecto-calreticulin expression in multiple myeloma correlates with a failed anti-tumoral immune response and bad prognosis.
Oncoimmunology
; 11(1): 2141973, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36338146
5.
Relevance of infections on the outcomes of patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents: a cohort study from the GESMD.
Ther Adv Hematol
; 13: 20406207221127547, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36199837
6.
Expanded NK cells from umbilical cord blood and adult peripheral blood combined with daratumumab are effective against tumor cells from multiple myeloma patients.
Oncoimmunology
; 10(1): 1853314, 2020 12 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-33457074
Resultados
1 -
6
de 6
1
Próxima >
>>